IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IDYA is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has meaningful bullish analyst support and a strong clinical catalyst backdrop, but the current pre-market drop, mixed technical setup, and lack of fresh news make this more of a hold than an immediate buy at this exact moment. If the investor is impatient and wants to act now, this is still not the best entry because price is below the pivot and momentum is not yet confirming upside.
The short-term trend is weak to neutral. Pre-market price is 28.28, down 2.82%, and below the pivot level of 31.149. RSI_6 at 35.234 is neutral but leaning weak, MACD histogram at -0.37 is below zero though contracting, and moving averages are converging, which suggests a possible stabilization but not a confirmed uptrend. Support is near S1 at 28.591 and S2 at 27.011, so the stock is currently testing support rather than breaking out. The stock trend model suggests upside potential over the next week and month, but the current tape does not show a strong immediate buy setup.
The company had a strong revenue increase in the latest quarter, and the clinical program remains the central long-term value driver.
There is no fresh news in the recent week to extend the catalyst momentum. The stock is trading lower in pre-market, which shows immediate selling pressure despite the positive analyst narrative. Technical momentum is not yet confirmed, and the company still posted a large net loss and negative EPS in the latest quarter. Hedge fund and insider trading trends are neutral, so there is no supportive buying signal from those groups. No recent congress trading data or influential figure transactions were reported.
In 2025/Q4, revenue increased 55.37% year over year to $10.876 million, which is a strong growth signal for a clinical-stage biotech. However, net income worsened to -$83.273 million and EPS fell to -0.94, showing the company is still deeply unprofitable. Gross margin was 100%, consistent with biotech economics, but the main takeaway is that the company is improving revenue while still burning heavily on R&D and operations. The latest quarter season is 2025/Q4.
Wall Street sentiment is strongly positive. Recent updates show Wedbush, Guggenheim, RBC Capital, Truist, and Citi all either raised price targets or reiterated bullish ratings after the positive OptimUM-02 data. Price targets were lifted to the low-to-mid $50s, with some as high as $65. The pros see meaningful clinical derisking, stronger odds of success for darovasertib, and a potential path to approval and commercialization. The main con is that the current share price has not yet confirmed a sustained technical breakout, so the bullish fundamental view is ahead of the chart.
